ADMA: ADMA Biologics, Inc.
About
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
Current Value
$20.631 Year Return
Current Value
$20.631 Year Return
Key Details
Market Cap
$4.88B
P/E Ratio
74.67
1Y Stock Return
423.60%
1Y Revenue Growth
63.39%
Dividend Yield
0.00%
Price to Book
21.0
Strategies that include ADMA
Stock's related to ADMA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CARG | 58.94% | $3.68B | +69.13% | 0.00% |
| SG | 54.75% | $4.38B | +299.68% | 0.00% |
| G | 54.11% | $7.83B | +31.86% | 1.34% |
| DOCS | 53.75% | $9.62B | +114.35% | 0.00% |
| BLFS | 45.21% | $1.04B | +64.64% | 0.00% |
| DOCN | 44.98% | $3.51B | +33.83% | 0.00% |
| RCUS | 42.63% | $1.33B | +5.07% | 0.00% |
| ITOS | 40.56% | $288.62M | -19.06% | 0.00% |
| ACLX | 40.19% | $4.74B | +69.19% | 0.00% |
| NTRA | 40.03% | $21.40B | +200.46% | 0.00% |
| NVAX | 39.47% | $1.28B | +49.53% | 0.00% |
| WAT | 38.77% | $20.47B | +25.51% | 0.00% |
| TARS | 36.43% | $1.79B | +166.88% | 0.00% |
| QNTM | 35.82% | $9.19M | -94.36% | 0.00% |
| IAG | 35.77% | $3.16B | +128.93% | 0.00% |
| PRLB | 35.59% | $907.12M | +1.96% | 0.00% |
| PAR | 35.52% | $2.72B | +98.12% | 0.00% |
| TY | 34.46% | - | - | 3.32% |
| CDNA | 34.20% | $1.18B | +132.21% | 0.00% |
| PDFS | 34.02% | $1.17B | -2.56% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UPLD | 0.07% | $87.26M | -26.39% | 0.00% |
| BBWI | -0.10% | $6.67B | +2.60% | 1.99% |
| CYCN | 0.12% | $4.77M | -16.19% | 0.00% |
| CLW | -0.14% | $413.53M | -30.06% | 0.00% |
| CI | 0.19% | $89.70B | +12.57% | 1.68% |
| IMRN | -0.34% | $10.31M | -5.04% | 0.00% |
| TEM | -0.35% | $8.50B | 0.00% | 0.00% |
| TBI | -0.40% | $199.52M | -50.80% | 0.00% |
| MRO | 0.41% | $16.08B | +13.59% | 1.53% |
| SLF | 0.45% | $34.74B | +18.95% | 3.89% |
| BDTX | 0.47% | $144.29M | +14.35% | 0.00% |
| TTEC | 0.50% | $204.76M | -76.19% | 1.39% |
| BSM | -0.52% | $3.17B | -13.01% | 10.65% |
| PG | -0.54% | $402.15B | +14.14% | 2.33% |
| XBIO | -0.58% | $6.01M | +21.36% | 0.00% |
| LMT | 0.58% | $126.40B | +18.99% | 2.36% |
| NKE | 0.64% | $110.02B | -30.63% | 2.01% |
| NEUE | -0.65% | $40.93M | -34.13% | 0.00% |
| TH | -0.70% | $839.02M | -24.49% | 0.00% |
| BACK | -0.71% | $1.76M | -32.90% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVD | -30.30% | $182.80M | -32.45% | 1.42% |
| PCRX | -26.40% | $772.48M | -37.25% | 0.00% |
| HUSA | -17.84% | $16.69M | -11.56% | 0.00% |
| MGNX | -17.05% | $218.42M | -53.04% | 0.00% |
| FAT | -16.46% | $89.30M | -11.53% | 10.73% |
| NFE | -16.17% | $2.29B | -74.75% | 3.32% |
| FATBB | -15.87% | $81.94M | -12.91% | 11.69% |
| MITK | -15.65% | $401.51M | -22.13% | 0.00% |
| ASPS | -14.72% | $22.36M | -80.26% | 0.00% |
| OKLO | -13.64% | $2.66B | +111.04% | 0.00% |
| KEP | -12.87% | $11.16B | +25.58% | 0.00% |
| UEIC | -12.85% | $148.52M | +43.22% | 0.00% |
| FIGS | -12.68% | $840.56M | -25.56% | 0.00% |
| RWAY | -12.12% | $394.72M | -17.18% | 15.47% |
| PULM | -11.43% | $19.83M | +202.98% | 0.00% |
| COLL | -10.72% | $959.44M | +16.71% | 0.00% |
| CBOE | -10.53% | $21.46B | +15.84% | 1.11% |
| AMN | -9.84% | $953.75M | -62.61% | 0.00% |
| PUBM | -9.40% | $739.82M | -2.82% | 0.00% |
| UUU | -9.04% | $4.97M | -41.89% | 0.00% |
ETF's related to ADMA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PTH | 49.76% | $143.31M | 0.6% |
| XBI | 41.42% | $6.58B | 0.35% |
| IBB | 40.36% | $6.66B | 0.45% |
| IWO | 38.67% | $12.56B | 0.24% |
| QQA | 38.64% | $135.01M | 0% |
| FFTY | 38.58% | $67.59M | 0.8% |
| XAR | 38.24% | $2.56B | 0.35% |
| FHLC | 37.98% | $2.73B | 0.084% |
| PBE | 37.90% | $258.53M | 0.58% |
| ISCG | 37.65% | $640.00M | 0.06% |
| FNY | 37.57% | $372.31M | 0.7% |
| VHT | 37.35% | $17.06B | 0.1% |
| IWP | 36.93% | $17.19B | 0.23% |
| FTHI | 36.88% | $1.01B | 0.75% |
| VOT | 36.50% | $15.26B | 0.07% |
| SMMV | 36.32% | $321.07M | 0.2% |
| VBK | 36.18% | $19.31B | 0.07% |
| SFYX | 36.15% | $105.21M | 0.06% |
| QGRO | 36.08% | $1.02B | 0.29% |
| PFUT | 35.99% | $326.69M | 0.64% |
News
Finnhub
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Yahoo
ADMA Biologics, Inc.'s ( NASDAQ:ADMA ) strong earnings report was rewarded with a positive stock price move. Our...
Yahoo
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Yahoo
A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.